Navigation Links
Board of Directors of Milestone Scientific Names Joseph D'Agostino Chief Financial Officer
Date:10/14/2008

LIVINGSTON, N.J., Oct. 14 /PRNewswire-FirstCall/ -- The Board of Directors of Milestone Scientific Inc. (OTC Bulletin Board: MLSS), the recognized leader in advanced injection technologies, today announced that it has officially appointed Joseph D'Agostino as the Company's Chief Financial Officer, effective immediately. Since January of this year, D'Agostino has been serving as Milestone's Acting Chief Financial Officer.

"We recognize that Milestone's future growth and success will be closely linked to the individuals chosen for key leadership positions," stated Joe Martin, Chief Executive Officer of Milestone. "For the past nine months, Joseph has demonstrated a commitment to excellence and a dedication to results that has allowed Milestone to achieve material cost savings and expense reductions across all areas of our operations. Moreover, he has proven to be a very important addition to our management team who has succeeded at winning the respect and trust of our employees and business partners. He has definitely earned this appointment and will surely persist in contributing to Milestone's future achievements."

As previously reported, D'Agostino is a results-oriented and decisive leader who has specific proven expertise in treasury and cash management, strategic planning, information technology, internal controls, Sarbanes-Oxley compliance, operations and financial and tax accounting. Before joining Milestone in January 2008, D'Agostino served as Senior Vice President and Treasurer of Summit Global Logistics, a publicly traded, full service international freight forwarder and customs broker with operations in the United States and China.

Previous executive posts also included Executive Vice President and CFO of Haynes Security, Inc., a leading electronic and manned security solutions company serving government agencies and commercial enterprises; Executive Vice President of Finance and Administration for Casio, Inc., the U.S. subsidiary of Casio Computer Co., Ltd., a leading manufacturer of consumer electronics with subsidiaries throughout the world; and Manager of Accounting and Auditing for Main Hurdman's (KPMG) national office in New York City. D'Agostino is a Certified Public Accountant and holds memberships in the American Institute of CPA's, New Jersey Society of CPA's, Financial Executive Institute, Consumer Electronics Industry Association and Homeland Security Industry Association. He is a graduate of William Paterson University where he earned a Bachelor of Arts degree in Science.

About Milestone Scientific Inc.

Headquartered in Livingston, New Jersey, Milestone Scientific is engaged in pioneering proprietary, highly innovative technological solutions for the medical and dental markets. Central to the Company's IP platform and product development strategy is its patented CompuFlo(R) technology for the improved and painless delivery of local anesthetic. Specifically, CompuFlo is a computer-controlled, pressure sensitive infusion, perfusion, suffusion and aspiration technology, which provides real-time readouts of pressures, fluid densities and flow rates, enabling the advanced delivery and removal of a wide array of fluids. The STA(TM) (Single Tooth Anesthesia) System computer-controlled local anesthesia delivery system which uses this technology provides dentists with audible and visual signals as to in-tissue pressure. Milestone's existing painless injection systems are currently sold in 25 countries. For more information on these and other innovative Milestone products, please visit the Company's web sites found at http://www.milesci.com and http://www.STAis4U.com.

Safe Harbor Statement

This press release may contain forward-looking statements regarding the timing and financial impact of the Milestone's ability to implement its business plan, expected revenues and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report on Form 10-KSB for the year ended December 31, 2007. The forward looking-statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
FOR MORE INFORMATION, PLEASE CONTACT:

Elite Financial Communications Group

Dodi Handy, President and CEO

For Media Inquiries: Tiffany Korkis or John Morrison, Directors, Elite Media Group

407-585-1080 or via email at mlss@efcg.net


'/>"/>
SOURCE Milestone Scientific Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. BioNanomatrix Announces Appointment of Dr. Pui-Yan Kwok to Its Scientific Advisory Board
2. WuXi PharmaTech Appoints Jeff Leng to Its Board of Directors
3. Stem Cell Leader Beike Signs 8 New Cooperation Agreements, Establishes Safety Monitoring Boards
4. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
5. BioXcel Forms a Corporate Advisory Board for Its Next Phase of Growth
6. BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board
7. Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
8. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
9. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
10. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
11. Two Top-Ranking Schools Join Jobs Board Site
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... MarketNewsUpdates.com News Commentary  ... The traditional ways to ... as of late due to the rise of the opioid ... dramatic impact on patient,s quality of life as Biotech and ... new forms of opioid formulations that prevent abuse. Biotech and ...
(Date:3/22/2017)... (PRWEB) , ... March 21, 2017 , ... Okyanos Cell ... seminar as part of their live events series, “Stem Cell Therapy: The Next Phase ... facility under the 2013 Stem Cell Research and Therapy Act, Okyanos maintains ...
(Date:3/22/2017)... ... March 21, 2017 , ... ... peristaltic pump with patented ReNu single-use (SU) cartridge technology. Engineered by the ... feed pumps in SU tangential flow filtration (TFF), virus filtration (VF) and ...
(Date:3/22/2017)... March 22, 2017  Personal Genome Diagnostics Inc. ... testing contract with the U.S. Department of Veterans ... assay with the company,s new CancerSELECT ™ ... actionable pan-cancer profiling test that includes microsatellite instability ... patient response to checkpoint inhibitor immunotherapies. CancerSELECT 125 ...
Breaking Biology Technology:
(Date:2/16/2017)... SAN FRANCISCO , Feb. 16, 2017 /PRNewswire/ ... research, today announced that it has received Laboratory ... The CAP Accreditation is presented to laboratories that ... and who demonstrate scientifically rigorous processes. ... of excellence in laboratory practices. We,re honored to ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
Breaking Biology News(10 mins):